1003.15
2.38%
ICICI Securities Limited
Vijaya Diagnostic Centre’s (Vijaya) Q4FY23 performance was driven by a steady 22.4% YoY growth in non-covid business, while covid business’ contribution fell to 1% (15% in Q4FY22). Overheads of new centres impacted EBITDA margin to a small extent though, at 40.6% in Q4, it continues to be better than that of most of listed peers.
Vijaya Diagnostic Centre Ltd. is trading above its 100 day SMA of 990.4
More from Vijaya Diagnostic Centre Ltd.
Recommended